120 participants
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2016-06-13
- Start Date:
- 2008-08-31
- Completion:
- 2014-06-30
Conditions
- Metastatic Breast Cancer
Interventions
- DRUG